IBRX Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PIRKIMAS 107250 min ago

@ $4.52

Išleistas: 14 vas. 2024 @ 20:58

Grąža: 62.79%

Ankstesnis signalas: vas. 14 - 16:30

Ankstesnis signalas: Pardavimas

Grąža: 4.24 %

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Stats
Šios dienos apimtis	39.08M
Vidutinė apimtis	5.40M
Rinkos kapitalizacija	4.95B
EPS	$-0.350 ( 2024-03-20 )
Kita pelno data	( $-0.160 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.39
ATR14	$0.117 (1.59%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-22	Simon Barry J.	Buy	159 146	Stock Option (right to buy)
2024-02-22	Simon Barry J.	Buy	45 731	Restricted Stock Units
2024-02-22	Lauer Regan J	Buy	42 439	Stock Option (right to buy)
2024-02-22	Lauer Regan J	Buy	12 195	Restricted Stock Units
2024-02-22	Sachs David C.	Buy	424 390	Stock Option (right to buy)

INSIDER POWER
99.24
Last 97 transactions
Buy: 228 380 025 \| Sell: 921 083

Tūris Koreliacija

Ilgas: 0.53 (weak)

Trumpas: -0.15 (neutral)

Signal:(48.073) Neutral

ImmunityBio, Inc. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
SIRI	0.928
RGF	0.928
FGBI	0.925
AROW	0.921
ALRS	0.92
GNTY	0.92
CBNK	0.915
GSMG	0.914
GOOD	0.906
ALLK	0.906

10 Labiausiai neigiamai susiję koreliacijos
RIVE	-0.933
DSEY	-0.93
DUOL	-0.927
AMPH	-0.926
RAM	-0.919
INTA	-0.919
PLYA	-0.918
ALTR	-0.91
DAIO	-0.909
MLTX	-0.907

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

ImmunityBio, Inc. Koreliacija - Valiuta/Žaliavos

-0.24
( neutral )

-0.50
( weak negative )

0.00
( neutral )

0.28
( neutral )

0.00
( neutral )

0.19
( neutral )

ImmunityBio, Inc. Finansinės ataskaitos

Annual	2023
Pajamos:	$622 000
Bruto pelnas:	$-17.89M (-2 876.21 %)
EPS:	$-1.150

FY	2023
Pajamos:	$622 000
Bruto pelnas:	$-17.89M (-2 876.21 %)
EPS:	$-1.150

FY	2022
Pajamos:	$240 000
Bruto pelnas:	$-23.95M (-9 980.00 %)
EPS:	$-1.040

FY	2021
Pajamos:	$934 000
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-0.893

Financial Reports:

No articles found.

ImmunityBio, Inc.

ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.